← back to search

Andrea Vecchione

IRCCS Humanitas Research Hospital · IT
Area of research
Cancer Research · Genetics
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Genetics and Neurodevelopmental Disorders, and Epigenetics and DNA Methylation.
h-index
49
citations
14,788
works
436
NIH funding
primary concept
Medicine
email

Recent publications

Non-Invasive Detection of Tumors by Volatile Organic Compounds in Urine.
2025cited by 9position: contributordoi
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines.
2025cited by 5position: contributordoi
Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications
Cancers 2025cited by 3position: middledoi
Storage Time and DNA Quality Determine <i>BRCA1/2</i> Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications.
2025cited by 3position: contributordoi
Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.
2025cited by 2position: contributordoi
Trends in Thyroid Fine-Needle Aspiration Cytology - Results from the Italian Cytopathology Committee National Practice Survey
Pathologica 2025cited by 1position: middledoi
miR-1297 is frequently downmodulated in flat epithelial atypia of the breast and promotes mammary neoplastic transformation via EphrinA2 regulation.
2025cited by 1position: contributordoi
Clinicopathologic Features of Isolated AFOP Nodules Radiologically Mimicking Malignancy in Post COVID-19 Patients: A Case Series Study.
2025cited by 0position: contributordoi
High-Throughput Molecular Characterization of the Microbiome in Breast Implant-Associated Anaplastic Large Cell Lymphoma and Peri-Implant Benign Seromas.
2025cited by 0position: contributordoi
Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma.
2024cited by 10position: contributordoi
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
2024cited by 10position: contributordoi
Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study.
2024cited by 2position: contributordoi
Prognostic Factors of Non-Predominant-Lepidic Lung Adenocarcinoma Presenting as Ground Glass Opacity: Results of a Multicenter Study.
2024cited by 2position: contributordoi
Author Correction: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
2024cited by 1position: contributordoi
Is CT Radiomics Superior to Morphological Evaluation for pN0 Characterization? A Pilot Study in Colon Cancer.
2024cited by 1position: contributordoi
The Multifaceted Complexity of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS): A Case Report Highlighting Atypical Gastrointestinal Manifestations.
2024cited by 0position: contributordoi
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.
2024cited by 0position: contributordoi
Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer.
2023cited by 66position: contributordoi
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis.
2023cited by 41position: contributordoi
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
2023cited by 26position: contributordoi
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.
2023cited by 23position: contributordoi
Role of Fra-2 in cancer
Cell Death & Differentiation 2023cited by 20position: contributordoi
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance.
2023cited by 16position: contributordoi
Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin.
2023cited by 11position: contributordoi
Histologic Analysis of Idiopathic Pulmonary Fibrosis by Morphometric and Fractal Analysis.
2023cited by 1position: contributordoi
Loss of CDKN1B induces an age-related clonal hematopoietic disorder via Notch2 activity dysregulation.
2023cited by 1position: contributordoi
Author Correction: Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer.
2023cited by 1position: contributordoi
Data from Alterations of the Tumor Suppressor Gene <i>ARLTS1</i> in Ovarian Cancer
2023cited by 0position: middledoi
Data from Alterations of the Tumor Suppressor Gene <i>ARLTS1</i> in Ovarian Cancer
2023cited by 0position: middledoi
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review.
2022cited by 45position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 39 papers (2019–2025)Gustavo Baldassarre · Sidney Kimmel Cancer Center16 papers (2019–2025)Barbara Belletti · Centro di Riferimento Oncologico12 papers (2019–2024)Gennaro Ciliberto · Istituti Fisioterapici Ospitalieri10 papers (2020–2023)Stefano Volinia · University of Ferrara8 papers (2012–2021)Massimiliano Mancini · Azienda Ospedaliera Sant'Andrea8 papers (2021–2025)Arianna Di Napoli · Azienda Ospedaliera Sant'Andrea7 papers (2020–2025)Carlo M. Croce · The Ohio State University7 papers (2012–2023)Rita Mancini · Azienda Ospedaliera Sant'Andrea7 papers (2020–2023)Gian Luca Rampioni Vinciguerra · Cancer Genetics (United States)7 papers (2020–2024)Hideshi Ishii · Osaka University Hospital6 papers (2022–2025)Marco Galasso · Eli Lilly (United States)5 papers (2012–2021) · 5 papers (2022–2025)Monica Schiappacassi · Centro di Riferimento Oncologico5 papers (2019–2024)Raffaele Giusti · Sapienza University of Rome4 papers (2020–2021)Gianpiero Di Leva · University of Manchester4 papers (2018–2023)Claudia De Vitis · MDPI4 papers (2022–2024)Ryota Chijimatsu · 4 papers (2021–2022)Marcello Maugeri‐Saccà · National Cancer Institute3 papers (2020–2021) · 3 papers (2013–2019)